ENZN earnings analysis
What we found in ENZN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Viskase reported Q2 2026 revenue of $90.131 million, down 7.3% year over year, with temporary restructuring-related production constraints driving a $10.9 million volume decline. Gross margin was 12.3%, broadly near the prior-year level, while the operating loss narrowed to $2.015 million and net loss improved materially to $5.133 million. The principal concern is liquidity: first-half operating cash flow was negative $27.520 million, and management explicitly reports substantial doubt about going concern unless the senior facility is refinanced before August 2027.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Q2 operating loss narrowed by $0.615M
- Operating loss narrowed 23.4% to $2.015 million in Q2 2026 from $2.630 million a year earlier, as SG&A declined $0.780 million to $12.149 million.
- Net loss improved by $15.125M YoY
- Net loss improved to $5.133 million from $20.258 million in Q2 2025, a $15.125 million reduction, helped by a sharply lower income-tax provision of $0.305 million versus $14.353 million.
- EMEA reported sales rose 10.9%
- EMEA reported-sales growth was $5.435 million, or 10.9%, to $50.038 million in Q2. Management attributes $5.3 million of the increase to intercompany sales volume.
- Credit facility maturity extended to 2027
- The April 2026 credit amendment extended the senior-credit-facility maturity by one year, from August 13, 2026 to August 13, 2027. The company reported $5.8 million of unused facility capacity, net of letters of credit, at June 30.
- YTD operating loss improved $10.683M
- Six-month operating loss improved $10.683 million to $6.348 million from $17.031 million, primarily because prior-year results included $12.100 million of asset impairment expense.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern doubt ahead of Aug. 2027 refinancing
- Management states substantial doubt about going concern because continued operations depend on refinancing the senior credit facility before its August 13, 2027 maturity. Cash was only $7.9 million and unused senior-facility capacity was $5.8 million at June 30, 2026.
- Cash burn reached $27.520M in operating cash flow
- Operating cash flow swung to a $27.520 million outflow for the first six months of 2026 from $2.373 million of inflow a year earlier, driven by higher receivables, inventories and other current assets plus lower accounts payable. Investing outflows were another $16.682 million, primarily manufacturing and production-equipment capex.
- Capacity constraints caused a $10.9M volume decline
- Q2 external net sales fell $7.148 million, or 7.3%, to $90.131 million. Management cites $10.9 million of volume-related declines, partly offset by $2.6 million in price/mix and $1.1 million of favorable FX; North America reported sales fell $5.628 million and Asia fell $3.383 million.
- Restructuring had $17.697M of prior-year charges
- The Arkansas closure produced $17.697 million of restructuring-related charges in the first half of 2025, including $12.100 million of inventory write-offs. Management does not expect significant additional 2026 cash charges, but cautions it may not realize the anticipated cost savings and benefits.
- No Item 1A update; macro costs remain exposed
- This smaller reporting company omitted Item 1A risk-factor disclosure in this 10-Q, so no formal risk-factor changes versus the prior filing were provided. The MD&A nevertheless identifies exposure to tariffs, supply-chain disruption, energy and commodity costs, and geopolitical conditions; Q2 gross profit fell $0.536 million to $11.098 million.
What they reported.
What the company itself reported, taken out of the document.
- Gross margin
- 12.3%
- Operating margin
- -2.2%
- Segment
- Q2 net sales by reported geography (includes intercompany sales): North America $41.375 million, South America $11.040 million, EMEA $50.038 million, Asia $8.525 million; consolidated segment-table sales $110.978 million.
- Segment
- Consolidated external net sales were $90.131 million, down $7.148 million (7.3%) year over year; the difference from geographic sales reflects intercompany activity/eliminations.
What they said about what is next.
The 10-Q provides no explicit quantitative revenue or EPS outlook. Management expects operating cash flow, cash on hand, and borrowing availability to meet requirements for the foreseeable future, but also states substantial doubt exists about going concern pending refinancing before the August 13, 2027 credit-facility maturity.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 4, 2026
- For Q1 2026, Viskase Holdings, Inc. reported a revenue decline of 8.1% to $86.5 million compared to $94.2 million in Q1 2025, mainly impacted by volume decreases in North America and despite a favorable foreign currency…
- 10-K · April 29, 2026
- Enzon Pharmaceuticals, now known as Viskase Holdings, Inc., reported stagnant financial performance in its recent 10-K as it navigates significant structural changes following a merger and ultimate rebranding. Despite…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ENZN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever